Matches in SemOpenAlex for { <https://semopenalex.org/work/W2593675088> ?p ?o ?g. }
- W2593675088 endingPage "241" @default.
- W2593675088 startingPage "241" @default.
- W2593675088 abstract "Abstract Background: In the pivotal FIRST trial, at the pre-specified planned analysis for progression-free survival (PFS), treatment (Tx) with lenalidomide plus low-dose dexamethasone until disease progression (Rd continuous) improved outcomes for transplant-ineligible patients (pts) with newly diagnosed multiple myeloma (NDMM) compared with melphalan, prednisone, and thalidomide (MPT), as well as Rd for 18 cycles (Rd18; Benboubker, NEJM 2014). Rd18 was added as a third arm to investigate whether Rd continuous Tx would control progression of NDMM longer than Rd18. Here, we present the final analysis of the overall survival (OS) data from the trial. Methods: Transplant-ineligible pts with NDMM were randomized 1:1:1 to Rd continuous (with lenalidomide given on days 1-21 of 28-day cycles until disease progression), Rd18 (with lenalidomide given on days 1-21 of eighteen 28-day cycles), or MPT (twelve 42-day cycles); both Rd18 and MPT were 72 weeks in duration. The primary endpoint was PFS and the key secondary endpoint was OS; the primary comparison was Rd continuous vs MPT. Other secondary endpoints included time to second therapy (TTST) and safety. Time from randomization to second progression or death (PFS2) was an exploratory analysis. Response assessment used for PFS and PFS2 analysis was determined by investigators based on International Myeloma Working Group criteria. Results: At the time of cutoff for the final OS analysis (January 21, 2016), 52 of the 535 pts in the Rd continuous arm and none of the pts in the Rd18 (n = 541) and MPT (n = 547) arms continued to receive Tx. The median follow-up for surviving pts was 67.0 months (range, 0-86.8 months). In the pre-specified final OS analysis for the primary comparison, a statistically significant advantage in OS was shown with Rd continuous over MPT (hazard ratio [HR], 0.78; 95% confidence interval [CI], 0.67-0.92; P = .00234; Table). OS for Rd continuous vs Rd18 was evaluated (HR, 1.02; 95% CI, 0.86-1.20). In this updated analysis, a PFS advantage continued to be seen for Rd continuous vs MPT (HR, 0.69; 95% CI, 0.59-0.79; P < .00001) and vs Rd18 (HR, 0.70; 95% CI, 0.60-0.81). Median TTST was longer for Rd continuous vs MPT (HR, 0.63; 95% CI, 0.54-0.73; Table). More pts in the Rd18 and MPT arms started second-line therapy (n = 377 and 381, respectively) compared with the Rd continuous arm (n = 299). Pts received a variety of Tx at progression, with bortezomib-based regimens the most common in the Rd continuous (n = 179; 59.9%), Rd18 (n = 208; 55.2%), and MPT (n = 170; 44.6%) arms. Pts who received bortezomib after Rd continuous or Rd18 had better outcomes than those who received it after MPT. PFS2 for Rd continuous was improved vs MPT (HR, 0.74; 95% CI, 0.64-0.85). Grade 3/4 adverse events (AEs) occurred in 86.3%, 80.2%, and 88.7% of the 532, 540, and 541 pts in the safety populations of the Rd continuous, Rd18, and MPT arms, respectively; the most common grade 3/4 AEs were neutropenia (29.5%, 26.5%, and 44.9%) and infections (31.6%, 21.9%, and 17.2%), and no new safety signals were seen compared with earlier analyses. Study discontinuation was most commonly due to disease progression and was less common in the Rd continuous vs Rd18 and MPT arms (50.7% vs 66.9% and 61.6%, respectively). Discontinuation due to AEs was similar across the Rd continuous, Rd18, and MPT arms (12.0%, 13.1%, and 13.9%). Solid tumor second primary malignancies (SPMs) occurred in 6.0, 6.9%, and 5.9% of pts, and hematologic malignancies occurred in 0.8%, 0.4%, and 2.6% of pts in the Rd continuous, Rd18, and MPT arms, respectively. Conclusions: Rd continuous significantly prolonged PFS and OS, and improved other secondary endpoints compared with MPT in transplant-ineligible pts with NDMM. Rd continuous also showed a PFS benefit compared with Rd18, delaying the time to next Tx. PFS2 outcomes suggest that Rd does not induce resistant relapses. Few hematologic malignancies occurred in the Rd arms, and the incidence of SPMs was similar between Rd continuous and Rd18. Rd continuous remains a standard of care for transplant-ineligible pts with NDMM. Disclosures Facon: Celgene: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: travel and expense, Speakers Bureau. Dimopoulos:Genesis: Consultancy, Honoraria; Celgene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Amgen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Janssen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Novartis: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees. Dispenzieri:Celgene: Research Funding. Belch:Takeda: Honoraria; Janssen: Honoraria; Amgen: Honoraria; Celgene: Honoraria. Cavo:Bristol-Myers Squibb: Consultancy, Honoraria; Janssen-Cilag: Consultancy, Honoraria; Amgen: Consultancy, Honoraria; Celgene: Consultancy, Honoraria; Millennium: Consultancy, Honoraria. Weisel:BMS: Consultancy, Honoraria; Amgen: Consultancy, Honoraria; Janssen: Consultancy, Honoraria, Research Funding; Celgene: Consultancy, Honoraria, Research Funding; Onyx: Consultancy, Research Funding; Takeda: Consultancy, Research Funding; Novartis: Consultancy, Research Funding. Ludwig:Janssen: Speakers Bureau; BMS: Speakers Bureau; Takeda: Research Funding, Speakers Bureau; Amgen: Research Funding, Speakers Bureau. Bahlis:BMS: Honoraria; Amgen: Consultancy, Honoraria; Celgene: Consultancy, Honoraria, Other: Travel Expenses, Research Funding, Speakers Bureau; Janssen: Consultancy, Honoraria, Other: Travel Expenses, Research Funding, Speakers Bureau; Onyx: Consultancy, Honoraria. Delforge:Janssen: Honoraria; Celgene: Honoraria; Amgen: Honoraria. Cavenagh:Amgen: Consultancy, Speakers Bureau; Novartis: Consultancy, Speakers Bureau; Janssen: Consultancy, Speakers Bureau; Celgene: Consultancy, Speakers Bureau. Geraldes:Celgene: Consultancy, Honoraria; Amgen: Consultancy, Honoraria; BMS: Consultancy, Honoraria; Janssen: Consultancy, Honoraria. Oriol:Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees; Amgen: Honoraria, Membership on an entity's Board of Directors or advisory committees; Celgene: Honoraria, Membership on an entity's Board of Directors or advisory committees. De La Rubia:Amgen, Bristol, Celgene, Janssen: Consultancy, Speakers Bureau. White:Celgene: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding. Moreau:Celgene: Honoraria; Amgen: Honoraria; Takeda: Honoraria; Novartis: Honoraria; Janssen: Honoraria, Speakers Bureau; Bristol-Myers Squibb: Honoraria. Attal:janssen: Consultancy, Research Funding; amgen: Consultancy, Research Funding; celgene: Consultancy, Research Funding; sanofi: Consultancy. Ervin-Haynes:Celgene: Employment, Equity Ownership. Chen:Celgene: Employment, Equity Ownership. Houck:Celgene: Employment. Hulin:celgene: Honoraria; Bristol: Honoraria; Janssen: Honoraria; Amgen: Honoraria; takeda: Honoraria. Benboubker:Amgen: Honoraria, Membership on an entity's Board of Directors or advisory committees; Takeda: Honoraria, Membership on an entity's Board of Directors or advisory committees; Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees; Celgene: Honoraria, Membership on an entity's Board of Directors or advisory committees." @default.
- W2593675088 created "2017-03-16" @default.
- W2593675088 creator A5000308170 @default.
- W2593675088 creator A5000761302 @default.
- W2593675088 creator A5003338851 @default.
- W2593675088 creator A5003676516 @default.
- W2593675088 creator A5003681868 @default.
- W2593675088 creator A5006799794 @default.
- W2593675088 creator A5008156104 @default.
- W2593675088 creator A5012405296 @default.
- W2593675088 creator A5013530856 @default.
- W2593675088 creator A5016338515 @default.
- W2593675088 creator A5018685925 @default.
- W2593675088 creator A5022522496 @default.
- W2593675088 creator A5024315315 @default.
- W2593675088 creator A5025168447 @default.
- W2593675088 creator A5025996929 @default.
- W2593675088 creator A5028662013 @default.
- W2593675088 creator A5032464400 @default.
- W2593675088 creator A5032722606 @default.
- W2593675088 creator A5041987846 @default.
- W2593675088 creator A5045605051 @default.
- W2593675088 creator A5046116136 @default.
- W2593675088 creator A5050232977 @default.
- W2593675088 creator A5054952877 @default.
- W2593675088 creator A5061903335 @default.
- W2593675088 creator A5063422967 @default.
- W2593675088 creator A5065238694 @default.
- W2593675088 creator A5069449708 @default.
- W2593675088 creator A5071926851 @default.
- W2593675088 creator A5077367623 @default.
- W2593675088 creator A5079071165 @default.
- W2593675088 creator A5081233146 @default.
- W2593675088 creator A5089853890 @default.
- W2593675088 date "2016-12-02" @default.
- W2593675088 modified "2023-10-18" @default.
- W2593675088 title "Final Analysis of Overall Survival from the First Trial" @default.
- W2593675088 doi "https://doi.org/10.1182/blood.v128.22.241.241" @default.
- W2593675088 hasPublicationYear "2016" @default.
- W2593675088 type Work @default.
- W2593675088 sameAs 2593675088 @default.
- W2593675088 citedByCount "10" @default.
- W2593675088 countsByYear W25936750882017 @default.
- W2593675088 countsByYear W25936750882018 @default.
- W2593675088 countsByYear W25936750882019 @default.
- W2593675088 crossrefType "journal-article" @default.
- W2593675088 hasAuthorship W2593675088A5000308170 @default.
- W2593675088 hasAuthorship W2593675088A5000761302 @default.
- W2593675088 hasAuthorship W2593675088A5003338851 @default.
- W2593675088 hasAuthorship W2593675088A5003676516 @default.
- W2593675088 hasAuthorship W2593675088A5003681868 @default.
- W2593675088 hasAuthorship W2593675088A5006799794 @default.
- W2593675088 hasAuthorship W2593675088A5008156104 @default.
- W2593675088 hasAuthorship W2593675088A5012405296 @default.
- W2593675088 hasAuthorship W2593675088A5013530856 @default.
- W2593675088 hasAuthorship W2593675088A5016338515 @default.
- W2593675088 hasAuthorship W2593675088A5018685925 @default.
- W2593675088 hasAuthorship W2593675088A5022522496 @default.
- W2593675088 hasAuthorship W2593675088A5024315315 @default.
- W2593675088 hasAuthorship W2593675088A5025168447 @default.
- W2593675088 hasAuthorship W2593675088A5025996929 @default.
- W2593675088 hasAuthorship W2593675088A5028662013 @default.
- W2593675088 hasAuthorship W2593675088A5032464400 @default.
- W2593675088 hasAuthorship W2593675088A5032722606 @default.
- W2593675088 hasAuthorship W2593675088A5041987846 @default.
- W2593675088 hasAuthorship W2593675088A5045605051 @default.
- W2593675088 hasAuthorship W2593675088A5046116136 @default.
- W2593675088 hasAuthorship W2593675088A5050232977 @default.
- W2593675088 hasAuthorship W2593675088A5054952877 @default.
- W2593675088 hasAuthorship W2593675088A5061903335 @default.
- W2593675088 hasAuthorship W2593675088A5063422967 @default.
- W2593675088 hasAuthorship W2593675088A5065238694 @default.
- W2593675088 hasAuthorship W2593675088A5069449708 @default.
- W2593675088 hasAuthorship W2593675088A5071926851 @default.
- W2593675088 hasAuthorship W2593675088A5077367623 @default.
- W2593675088 hasAuthorship W2593675088A5079071165 @default.
- W2593675088 hasAuthorship W2593675088A5081233146 @default.
- W2593675088 hasAuthorship W2593675088A5089853890 @default.
- W2593675088 hasConcept C10515644 @default.
- W2593675088 hasConcept C126322002 @default.
- W2593675088 hasConcept C143998085 @default.
- W2593675088 hasConcept C71924100 @default.
- W2593675088 hasConceptScore W2593675088C10515644 @default.
- W2593675088 hasConceptScore W2593675088C126322002 @default.
- W2593675088 hasConceptScore W2593675088C143998085 @default.
- W2593675088 hasConceptScore W2593675088C71924100 @default.
- W2593675088 hasIssue "22" @default.
- W2593675088 hasLocation W25936750881 @default.
- W2593675088 hasOpenAccess W2593675088 @default.
- W2593675088 hasPrimaryLocation W25936750881 @default.
- W2593675088 hasRelatedWork W2159986890 @default.
- W2593675088 hasRelatedWork W2337677096 @default.
- W2593675088 hasRelatedWork W2554345814 @default.
- W2593675088 hasRelatedWork W2558534037 @default.
- W2593675088 hasRelatedWork W2896492909 @default.
- W2593675088 hasRelatedWork W2897496508 @default.
- W2593675088 hasRelatedWork W2946514268 @default.
- W2593675088 hasRelatedWork W3011827526 @default.